Los Angeles Capital Management
CRNX

Los Angeles Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Los Angeles Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Hold
9,821
– – ﹤0.01% 997
2026
Q1 		$357K Sell
9,821
-1,446
-13% -$64.6K ﹤0.01% 976
2025
Q4 		$488K Buy
11,267
+1,834
+19% +$81.6K ﹤0.01% 900
2025
Q3 		$393K Hold
9,433
– – ﹤0.01% 1021
2025
Q2 		$271K Buy
+9,433
New +$291K ﹤0.01% 1091

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's CRNX Position: Q2 2026 in Review

Los Angeles Capital Management held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 9,821 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #997.

Los Angeles Capital Management first reported a position in CRNX in Q2 2025 and has held it in 5 quarters since. The position peaked at $488K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Los Angeles Capital Management held 9,821 shares of Crinetics Pharmaceuticals worth $368K as of Q2 2026.
  • Los Angeles Capital Management left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #997 holding.
  • Los Angeles Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Los Angeles Capital Management's Crinetics Pharmaceuticals position peaked at $488K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.